AIR, acute inflammatory response; ALK, anaplastic lymphoma kinase; ANG, angiogenesis; APR, acute phase reaction; BRCA1/2, Breast Cancer Gene 1, Breast Cancer Gene 2; Biological scores; Biomarker; CA, complement activation; CI, confidence interval; CPH, Cox proportional hazards; CV, coefficient of variation; ECM, extracellular matrix organization; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; GLY, glycolysis; HR, hazard ratio; HbA1c, hemoglobin A1c; IFN1, interferon type 1 signaling and response; IFNg, Interferon γ signaling and response; IRn, type n immune response; IT, immune tolerance; LC MS-MS, liquid chromatography with tandem mass spectrometry; MALDI ToF, matrix-assisted laser desorption/ionization time of flight; MRM, multiple reaction monitoring; MS, mass spectral; Mass spectrometry; NSCLC, non-small cell lung cancer; OS, overall survival; PC, principal component; PCA, principal component analysis; PCn, principal component n; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Proteomics; QC, quality control; Serum proteome; Set enrichment analysis; WH, wound healing; m/Z, mass/charge